目的:结合生物信息学分析和PCR表达验证,探索子宫内膜癌(endometrial carcinoma, EC)肿瘤微环境中的预后关键基因。方法:下载获取TCGA数据库中552例EC患者的基因表达数据,应用R软件ESTIMATE算法进行免疫评分和基质评分,筛选表达差异基因。多种算法对差异基因的预后情况和相关通路进一步探索。PCR实验分析差异基因在细胞系中的表达相关性。结果:Cox回归分析和KM生存分析提示CCR4(C-C motif chemokine receptor 4,CCR4)为潜在预后相关基因。GSEA(gene set enrichment analysis,GSEA)、KEGG(kyoto encyclopedia of genes and genomes,KEGG)分析结果发现,CCR4在免疫应答-激活细胞表面受体信号通路中显著富集。RT-qPCR结果表明,在细胞水平,CCR4在肿瘤组的表达显著高于非肿瘤组。结论:子宫内膜癌的肿瘤微环境中存在免疫浸润,CCR4有望成为新的子宫内膜癌诊断标记物。
[1] Soslow RA, Tornos C, Park KJ, et al. Endometrial carcinoma diagnosis: use of figo grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists[J]. Int J Gynecol Pathol, 2019, 38 Suppl 1(Iss 1 Suppl 1): S64-S74.
[2] Travaglino A, Arciuolo D, Santoro A, et al. Corded and hyalinized endometrioid carcinoma: summary of clinical, histological, immunohistochemical and molecular data[J]. Pathol Res Pract, 2023, 247: 154515.
[3] Walsh CS, Hacker KE, Secord AA, et al. Molecular testing for endometrial cancer: an sgo clinical practice statement[J]. Gynecol Oncol, 2023, 168: 48-55.
[4] Marín-Jiménez JA, García-Mulero S, Matías-Guiu X, et al. Facts and hopes in immunotherapy of endometrial cancer[J]. Clin Cancer Res, 2022, 28(22): 4849-4860.
[5] Rousset-Rouviere S, Rochigneux P, Chrétien AS, et al. Endometrial carcinoma: immune microenvironment and emerging treatments in immuno-oncology[J]. Biomedicines, 2021, 9(6): 632.
[6] Ketcham JM, Marshall LA, Talay O. CCR4 antagonists inhibit T(reg) trafficking into the tumor microenvironment[J]. ACS Med Chem Lett, 2018, 9(10): 953-955.
[7] Yoshie O. CCR4 as a therapeutic target for cancer immunotherapy[J]. Cancers (Basel), 2021, 13(21): 5542.
[8] Zhang Y, Chen K, Li L, et al. CCR4 is a prognostic biomarker and correlated with immune infiltrates in head and neck squamous cell carcinoma[J]. Ann Transl Med, 2021, 9(18): 1443.
[9] Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48.
[10] Lu KH, Broaddus RR. Endometrial cancer[J]. N Engl J Med, 2020, 383(21): 2053-2064.
[11] Oaknin A, Bosse TJ, Creutzberg CL, et al. Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 33(9): 860-877.
[12] Cai Y, Wang B, Xu W, et al. Endometrial cancer: genetic, metabolic characteristics, therapeutic strategies and nanomedicine[J]. Curr Med Chem, 2021, 28(42): 8755-8781.
[13] Harkenrider MM, Abu-Rustum N, Albuquerque K, et al. Radiation therapy for endometrial cancer: an American society for radiation oncology clinical practice guideline[J]. Pract Radiat Oncol, 2023, 13(1): 41-65.
[14] Passarello K, Kurian S, Villanueva V. Endometrial cancer: an overview of pathophysiology, management, and care[J]. Semin Oncol Nurs, 2019, 35(2): 157-165.
[15] Vural F, Coşkun ADE, Çιtak G, et al. The comparison of inflammatory markers in geriatric and nongeriatric endometrial cancers[J]. Cancer Biomark, 2022, 34(4): 583-590.
[16] Xu M, Zhang T, Xia R, et al. Targeting the tumor stroma for cancer therapy[J]. Mol Cancer, 2022, 21(1): 208.
[17] Li BL, Wan XP. Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer[J]. J Cell Mol Med, 2020, 24(14): 7767-7777.
[18] Antomarchi J, Ambrosetti D, Cohen C, et al. Immunosuppressive tumor microenvironment status and histological grading of endometrial carcinoma[J]. Cancer Microenviron, 2019, 12(2-3): 169-179.
[19] He Y, Sun MM, Zhang GG, et al. Targeting PI3K/Akt signal transduction for cancer therapy[J]. Signal Transduct Target Ther, 2021, 6(1): 425.
[20] Diéguez-Martínez N, Espinosa-Gil S, Yoldi G, et al. The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival[J]. Cell Mol Life Sci, 2022, 79(10): 524.
[21] Li J, Ruffell B. Cytokines drive prostate cancer lineage plasticity[J]. Immunity, 2022, 55(10): 1761-1763.
[22] Zhang X, Luo Y, Cen Y, et al. MACC1 promotes pancreatic cancer metastasis by interacting with the EMT regulator SNAI1[J]. Cell Death Dis, 2022, 13(11): 923.
[23] Bogacka J, Pawlik K, Ciapała K, et al. CC chemokine receptor 4 (CCR4) as a possible new target for therapy[J]. Int J Mol Sci, 2022, 23(24): 15638.
[24] Ono S, Suzuki S, Kondo Y, et al. Trametinib improves treg selectivity of anti-CCR4 antibody by regulating CCR4 expression in CTLs in oral squamous cell carcinoma[J]. Sci Rep, 2022, 12(1): 21678.
[25] Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy[J]. Mol Cell, 2020, 78(6): 1019-1033.
[26] Zilio S, Bicciato S, Weed D, et al. CCR1 and CCR5 mediate cancer-induced myelopoiesis and differentiation of myeloid cells in the tumor[J]. J Immunother Cancer, 2022, 10(1): e003131.
[27] Shen W, Zhang X, Tang J, et al. CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis[J]. Theranostics, 2021, 11(5): 2297-2317.
[28] Meng J, Wang L, Hou J, et al. CCL23 suppresses liver cancer progression through the CCR1/AKT/ESR1 feedback loop[J]. Cancer Sci, 2021, 112(8): 3099-3110.
[29] Kanagawa N, Niwa M, Hatanaka Y, et al. CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma[J]. Int J Cancer, 2007, 121(9): 2013-2022.
